

CURRICULUM VITAE  
**David M. Faleck, MD**

Gastroenterology, Hepatology & Nutrition Service  
Memorial Sloan Kettering Center Center  
1275 York Avenue  
Howard 815  
New York, NY 10065  
Phone: 212-639-3904  
Fax: 212-639-2766  
[Faleckd@mskcc.org](mailto:Faleckd@mskcc.org)

**EDUCATION & POST-GRADUATE**

**TRAINING**

2015 – 2018 Icahn School of Medicine at Mount Sinai, New York, NY  
Fellow in Gastroenterology

2012 – 2015 Columbia University Medical Center / New York-Presbyterian Hospital  
New York, NY  
Intern and Resident in Internal Medicine

2008 – 2012 Albert Einstein College of Medicine, New York, NY  
Doctor of Medicine

2004 – 2008 University of Pennsylvania, Philadelphia, PA  
Bachelor of Arts in Biology, with honors  
Bachelor of Arts in Interdisciplinary Jewish Studies, with honors  
*Summa cum laude*

**ACADEMIC APPOINTMENTS**

2021 – Present Director of Inflammatory and Immune-Related Bowel Diseases, Memorial Sloan Kettering Center Center, New York, NY

2020 – Present Assistant Attending, Memorial Sloan Kettering Center Center, New York, NY

2020 – Present Assistant Professor of Medicine, Weill Cornell Medical College, New York, NY

2018 – 2020 Assistant Attending (L1), Memorial Sloan Kettering Center Center, New York, NY

2018 – 2020 Instructor in Medicine, Weill Cornell Medical College, New York, NY

**BOARD CERTIFICATIONS**

2018 – Present Gastroenterology: American Board of Internal Medicine

2015 – Present Internal Medicine: American Board of Internal Medicine

**LICENSURES**

2022 – Present New Jersey Medical License, Number 25MA11457400

2021 – Present Florida State Medical License, Number TPME3375

2015 – Present New York State Medical License, Number 279006

**HONORS & AWARDS**

- Castle Connolly Rising Star, 2021-2022

- New York Magazine: Top Doctors, 2022-2023
- Presidential Poster Award, ACG 2020
- "Best Oral Presentation" at DDW Research Preview Forum, New York Society of Gastrointestinal Endoscopy, 2018
- Golding Research Scholarship, merit scholarship awarded to attend Albert Einstein College of Medicine, 2008-2012
- *Alpha Omega Alpha* Honor Medical Society, Albert Einstein College of Medicine, 2011
- Goldin Endowment Award for "Best Student in Jewish Studies", University of Pennsylvania, 2008
- *Phi Beta Kappa* Honor Society, Junior Year inductee, University of Pennsylvania, 2007

### **INVITED PRESENTATIONS**

Gastroenterology Grand Rounds, Mount Sinai Hospital, New York, NY (2023)

"New Frontiers in Immune Checkpoint Inhibitor-Related Enterocolitis"

Gastroenterology Grand Rounds, Mount Sinai West, New York, NY (2023)

"Overview and Management of Immune Checkpoint Inhibitor-Related Enterocolitis"

American College of Gastroenterology Annual Post-Graduate Course, Charlotte, NC (2022)

"Immune Checkpoint Inhibitor Colitis and Other GI-Related Adverse Events"

Medical Scientist Grand Rounds, Icahn School of Medicine at Mount Sinai, New York, NY (2022)

"The Gut Microbiome in Immunotherapy-related Colitis"

Digestive Disease Week 2022, Session Moderator, San Diego, CA

"Update on Immune Checkpoint Inhibitor-Induced Enterocolitis"

Immuno-Oncology Translational Network, Semi-Annual Meeting, Virtual (2022)

"Characterizing and Predicting Colitis in Immune Checkpoint Blockade-treated Cancer Patients"

Crohn's & Colitis Congress 2022, Session Panelist, Virtual Conference

"Checkpoint Inhibitor Colitis"

GI Citywide Conference, University of Minnesota, Virtual Lecture (2021)

"Overview and Management of Immune Checkpoint Inhibitor-Related Enterocolitis"

IBD Conference, Icahn School of Medicine at Mount Sinai, New York, NY (2021)

"Characterizing and Predicting Colitis in Immune Checkpoint Blockade-treated Cancer Patients"

Total CME, Invited Speaker for Online Webinar (2020)

"How I Manage Gastrointestinal Immune-Related Adverse Events"

The New York Society for Gastrointestinal Endoscopy 44th Annual New York Course (2020),

"Overview and Management of Immune Checkpoint Inhibitor-Related Enterocolitis"

GI Division Grand Rounds, Icahn School of Medicine at Mount Sinai, New York, NY (2020)

"Overview and Management of Immune Checkpoint Inhibitor-Related Colitis"

Annual Alumni Meeting, Memorial Sloan Kettering Cancer Center, New York, NY (2019)

**“New Ways to Manage GI Toxicity of Immune Checkpoint Inhibitors”**

Surgical Grand Rounds, Memorial Sloan Kettering Cancer Center, New York, NY (2019)  
“Updates in Colitis 2019: C. difficile, IBD and Checkpoint-Inhibitor Related Disease”

Current Trends in Gastroenterology, Hepatology and Nutrition Annual Course, Memorial Sloan Kettering Cancer Center, New York, NY (2019)  
“Updates in Inflammatory Bowel Disease 2019”

Pediatric Grand Rounds, Memorial Sloan Kettering Cancer Center, New York, NY (2019)  
“Overview and Management of Immune Checkpoint Inhibitor-Related Colitis”

Approach to Gastrointestinal Premalignant Conditions: A 2019 Update, CME Course at Memorial Sloan Kettering Cancer Center, New York, NY (2019)  
“Endoscopic Surveillance and Management of Dysplasia in Inflammatory Bowel Disease”

PREDICTS NIH Collaboration Meeting, Uniformed Services University, Bethesda, MD (2019)  
“Immune Checkpoint Inhibitor-Related Enterocolitis: Drug-Induced IBD?”

Liver Diseases Grand Rounds, Icahn School of Medicine at Mount Sinai, New York, NY (2017)  
“Primary Sclerosing Cholangitis and Inflammatory Bowel Disease”

Crohn’s & Colitis Foundation Fellow Education Night, New York, NY (2016)  
“Inflammatory Bowel Disease 102: Complexities in IBD Management”

Gastroenterology Grand Rounds, Icahn School of Medicine at Mount Sinai, New York, NY (2016)  
“Positioning Biologics in Inflammatory Bowel Disease: Which, What Order and in Whom”

**INTRAMURAL TEACHING**

**a. INVITED PRESENTATIONS**

Best of DDW IBD 2023, Memorial Sloan Kettering Cancer Center, New York, NY (2023)

Resident Lecture, Memorial Sloan Kettering Cancer Center, New York, NY (2021, 2022)  
“Overview and Management of Immune Checkpoint Inhibitor-Related Enterocolitis”

Gastroenterology Service Conference, Memorial Sloan Kettering Cancer Center, New York, NY (2018 - Present)  
“Introduction to IBD Endoscopy”

Melanoma Research meeting, Memorial Sloan Kettering Cancer Center, New York, NY (2020)  
“Updates and Controversies in Immune Checkpoint Inhibitor-Related Colitis”

Genitourinary Oncology DMT meeting, Memorial Sloan Kettering Cancer Center, New York, NY (2019)  
“Overview and Management of Immune Checkpoint Inhibitor-Related Colitis”

Gastrointestinal Oncology DMT meeting, Memorial Sloan Kettering Cancer Center, New York, NY (2019)  
“Overview and Management of Immune Checkpoint Inhibitor-Related Colitis”

Melanoma DMT meeting, Memorial Sloan Kettering Cancer Center, New York, NY (2019)  
 “Predictors and Management of Immune Checkpoint Inhibitor-Related Colitis”

Gastroenterology Service Conference, Memorial Sloan Kettering Cancer Center, New York, NY (2018)  
 “Introduction to IBD Part 2: Medical and Surgical Management”

Gastroenterology Service Conference, Memorial Sloan Kettering Cancer Center, New York, NY (2018)  
 “Introduction to IBD Part 1: Disease Overview and Assessment”

Gastroenterology Nursing Conference, Memorial Sloan Kettering Cancer Center, New York, NY (2018)  
 “Introduction to IBD for Nurses”

**b. DIDACTICS**

Monthly IBD Conference for Fellows, Memorial Sloan Kettering Cancer Center, 2018-Present

Introduction to Colonoscopy Lecture for First Year Fellows, Memorial Sloan Kettering Cancer Center, 2019-Present

IBD and IBS Core Curriculum for Fellows, Memorial Sloan Kettering Cancer Center, 2020-Present

**GRANT AND CONTRACT SUPPORT:**

**A. Present Grants**

<b>Grant</b>	<b>Role</b>	<b>Dates</b>	<b>Total Costs</b>
Characterizing and predicting colitis in immune checkpoint blockade-treated cancer patients <i>UO1 1U01DK124165</i> <b>NIH/NIDDK</b> <b>PI: Gnjatic, Colombel &amp; Faith</b> <b>Site PI: Faleck</b>	<b>Consortium-site PI: 5%</b>	2020-2025	\$2,910,800
Fecal Microbiota Transplantation for Immune Checkpoint Inhibitor-Related Diarrhea: A Pilot Study <b>MSKCC</b> <b>PI: Faleck</b>	<b>PI: 5%</b>	2020-2023	\$100,000
Fecal Microbiota Transplantation National Registry <b>PI: Wu, Laine, Kelly</b> <b>Site PI: Faleck</b>	<b>Site PI</b>	2023 -	N/A (per patient fee)

**PEER-REVIEWED PUBLICATIONS**

1. Magahis PT, Satish D, Esther Babady N, Kamboj M, Postow MA, Laszkowska M, **Faleck DM**. Prevalence of Enteric Infections in Patients on Immune Checkpoint Inhibitors and Impact on

Management and Outcomes. *Oncologist*. 2023 Sep 18:oyad226. doi: 10.1093/oncolo/oyad226. Epub ahead of print. PMID: 37721546.

2. Liu C, Shatila M, Mathew A, Machado AP, Thomas A, Zhang HC, Thomas AS, **Faleck D**, Funchain P, Philpott J, Grivas P, Obeid M, Carbonnel F, Wang Y. Role of C-Reactive Protein in Predicting the Severity and Response of Immune-Mediated Diarrhea and Colitis in Patients with Cancer. *J Cancer*. 2023 Jun 26;14(10):1913-1919. doi: 10.7150/jca.84261. PMID: 37476185; PMCID: PMC10355204.
3. Badran YR, Zou F, Durbin SM, Dutra BE, Abu-Sbeih H, Thomas AS, Altan M, Thompson JA, Qiao W, Leet DE, Lai PY, Horick NK, Postow MA, Faleck DM\*, Wang Y\*, Dougan M\*. Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis. *J Immunother Cancer*. 2023 Jun;11(6):e007195. doi: 10.1136/jitc-2023-007195. PMID: 37349130. \*Co-Senior Authors
4. Satish D, Lin IH, Flory J, Gerdes H, Postow MA, **Faleck DM**. Exocrine Pancreatic Insufficiency Induced by Immune Checkpoint Inhibitors. *Oncologist*. 2023 Jun 7:oyad150. doi: 10.1093/oncolo/oyad150. Epub ahead of print. PMID: 37285223.
5. Thomas A, Lee SE, Shatila M, De Toni E, Török HP, Ben Khaled N, Powell N, Weight R, **Faleck DM\***, Wang Y\*. IL12/23 blockade for refractory immune-mediated colitis: 2 center experience. *Am J Gastroenterol*. 2023 May 22. doi: 10.14309/ajg.0000000000002332. Epub ahead of print. PMID: 37216614. \*Co-Senior Authors
6. **Faleck DM**, Dougan M, Tello MA, Grossman JE, Moss AC, Postow MA. Accelerating the evolution of immune-related enterocolitis management. *J Clin Oncol*. Faleck DM, Dougan M, Tello M, Grossman JE, Moss AC, Postow MA. Accelerating the Evolution of Immune-Related Enterocolitis Management. *J Clin Oncol*. 2023 Apr 11:JCO2202914. doi: 10.1200/JCO.22.02914. Epub ahead of print. PMID: 37040601.
7. Chatila WK, Walch H, Hechtman JF, Moyer SM, Sgambati V, **Faleck DM**, Srivastava A, Tang L, Benhamida J, Ismailgeci D, Campos C, Wu F, Chang Q, Vakiani E, de Stanchina E, Weiser MR, Widmar M, Yantiss RK, Shah MA, Bass AJ, Stadler ZK, Katz LH, Mellingshoff IK, Sethi NS, Schultz N, Ganesh K, Kelsen D, Yaeger R. Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancers. *Nat Commun*. 2023 Jan 7;14(1):110. doi: 10.1038/s41467-022-35592-9. PMID: 36611031.
8. Zheng-Lin B, **Faleck DM**, Harding JJ. Subacute Abdominal Pain in a Patient With Chronic Liver Disease and Hepatocellular Carcinoma. *JAMA Oncol*. 2022 Sep 22. doi: 10.1001/jamaoncol.2022.3888. Epub ahead of print. PMID: 36136344.
9. Kuo AM, Kraehenbuehl L, King S, Leung DYM, Goleva E, Moy AP, Lacouture ME, Shah NJ, **Faleck DM**. Contribution of the Skin-Gut Axis to Immune-Related Adverse Events with Multi-System Involvement. *Cancers (Basel)*. 2022 Jun 17;14(12):2995. doi: 10.3390/cancers14122995. PMID: 35740660; PMCID: PMC9221505.
10. Zou F\*, **Faleck D\***, Thomas A, Harris J, Satish D, Wang X, Charabaty A, Ernstoff MS, Glitza Oliva IC, Hanauer S, McQuade J, Obeid M, Shah A, Richards DM, Sharon E, Wolchok J, Thompson J, Wang Y. Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. *J Immunother Cancer*. 2021 Nov;9(11):e003277. doi: 10.1136/jitc-2021-003277. PMID: 34789551; PMCID:

11. Smithy JW, **Faleck DM**, Postow MA. Facts and Hopes in Prediction, Diagnosis, and Treatment of Immune-Related Adverse Events. *Clin Cancer Res.* 2022 Apr 1;28(7):1250-1257. doi: 10.1158/1078-0432.CCR-21-1240. PMID: 34921018; PMCID: PMC8976709.
12. Harris JP, Postow MA, **Faleck DM**. Efficacy of Infliximab Dose Escalation in Patients with Refractory Immunotherapy-Related Colitis: A Case Series. *Oncologist.* 2022 Apr 5;27(4):e350-e352. doi: 10.1093/oncolo/oyac019. PMID: 35380715; PMCID: PMC8982418.
13. Ngamruengphong S, Aihara H, Friedland S, Nishimura M, **Faleck D**, Benias P, Yang D, Draganov PV, Kumta NA, Borman ZA, Dixon RE, Marion JF, D'Souza LS, Tomizawa Y, Jit S, Mohapatra S, Charabaty A, Parian A, Lazarev M, Figueroa EJ, Hanada Y, Wang AY, Wong Kee Song LM. Endoscopic submucosal dissection for colorectal dysplasia in inflammatory bowel disease: a US multicenter study. *Endosc Int Open.* 2022 Apr 14;10(4):E354-E360. doi: 10.1055/a-1783-8756. PMID: 35433226; PMCID: PMC9010076.
14. Luo J, Beattie JA, Fuentes P, Rizvi H, Egger JV, Kern JA, Leung DYM, Lacouture ME, Kris MG, Gambarin M, Santomasso BD, **Faleck DM**, Hellmann MD. Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events. *J Thorac Oncol.* 2021 Jul 12:S1556-0864(21)02291-7. doi: 10.1016/j.jtho.2021.06.024. Epub ahead of print. PMID: 34265432.
15. Segal NH, Cercek A, Ku G, Wu AJ, Rimner A, Khalil DN, Reidy-Lagunes D, Cuaron J, Yang TJ, Weiser MR, Romesser PB, Stadler ZK, Varghese AM, Ganesh K, Yaeger R, Connell LC, **Faleck D**, Abou-Alfa GK, Mcauliffe KC, Vaishauskas P, Solter ML, Ogle M, Adamow MJ, Holland A, Vedantam P, Wong P, Merghoub T, Vakiani E, Hollmann TJ, Juluru K, Chou JF, Capanu M, Erinjeri J, Solomon S, Yamada Y, Kemeny N, Crane CH, Saltz LB. Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair-proficient Metastatic Colorectal Cancer. *Clin Cancer Res.* 2021 Apr 15;27(8):2200-2208. doi: 10.1158/1078-0432.CCR-20-2474. Epub 2021 Jan 27. PMID: 33504552.
16. Lukin D\*, **Faleck D\***, Xu R, Zhang Y\*, Weiss A, Aniwan S, Kadire S, Tran G, Rahal M, Winters A, Chablaney S, Koliani-Pace JL, Meserve J, Campbell JP, Kochhar G, Bohm M, Varma S, Fischer M, Boland B, Singh S, Hirten R, Ungaro R, Lasch K, Shmidt E, Jairath V, Hudesman D, Chang S, Swaminath A, Shen B, Kane S, Loftus Jr. EV, Sands BE, Colombel J-F, Siegel CA, Sandborn WJ, Dulai PS. Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis, *Clinical Gastroenterology and Hepatology* (2020), doi: <https://doi.org/10.1016/j.cgh.2020.10.003>. \*Co-first authors.
17. **Faleck DM**, Shmidt E, Huang R, Katta LG, Narula N, Pinotti R, Suarez-Farinas M, Colombel JF. Effect of Concomitant Therapy With Steroids and Tumor Necrosis Factor Antagonists for Induction of Remission in Patients With Crohn's Disease: a Systematic Review and Pooled Meta-analysis [published online ahead of print, 2020 Jun 19]. *Clin Gastroenterol Hepatol.* 2020;S1542-3565(20)30847-8. doi:10.1016/j.cgh.2020.06.036
18. Abu-Sbeih H\*, **Faleck DM\***, Ricciuti B, Mendelsohn RB, Naqash AR, Cohen JV, Sellers MC, Balaji A, Ben-Betzalel G, Hajir I, Zhang J, Awad M, Leonardi GC, Johnson DB, Pinato DJ, Owen DH, Weiss SA, Lamberti G, Lythgoe MP, Manuzzi L, Arnold C, Qiao W, Naidoo J, Markel G,

Powell N, Yeung SCJ, Sharon E, Dougan M, Wang Y. Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. *J Clin Oncol*. 2020 Feb 20. \*Co-first authors.

19. Dulai PS, Singh S, Castele NV, Meserve J, Winters A, Chablaney S, Aniwan S, Shashi P, Kochhar G, Weiss A, Koliyani-Pace JL, Gao Y, Boland BS, Chang JT, **Faleck D**, Hirten R, Ungaro R, Lukin D, Sultan K, Hudesman D, Chang S, Bohm M, Varma S, Fischer M, Shmidt E, Swaminath A, Gupta N, Rosario M, Jairath V, Guizzetti L, Feagan BG, Siegel CA, Shen B, Kane S, Loftus EV Jr, Sandborn WJ, Sands BE, Colombel JF, Lasch K, Cao C. Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis. *Clin Gastroenterol Hepatol*. 2020 Feb 13.
20. Koliyani-Pace JL, Singh S, Luo M, Hirten R, Aniwan S, Kochhar G, Chang S, Lukin D, Gao Y, Bohm M, Swaminath A, Gupta N, Shmidt E, Meserve J, Winters A, Chablaney S, **Faleck DM**, Yang J, Huang Z, Boland BS, Shashi P, Weiss A, Hudesman D, Varma S, Fischer M, Sultan K, Shen B, Kane S, Loftus EV, Sands BE, Colombel JF, Sandborn WJ, Lasch K, Siegel CA, Dulai PS. Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes. *Inflamm Bowel Dis*. 2019 May 3.
21. Adar T, **Faleck D**, Sasidharan S, Cushing K, Borren NZ, Nalagatla N, Ungaro R, Owen SC, Patel A, Cohen BL, Ananthakrishnan AN. Comparative safety and effectiveness of tumor necrosis factor  $\alpha$  antagonists and vedolizumab in older IBD patients: A multicenter study. *Aliment Pharmacol Ther*. 2019 Feb 17.
22. **Faleck DM**, Winters A, Chablaney S, Shashi P, Meserve J, Weiss A, Aniwan S, Koliyani-Pace JL, Kochhar G, Boland B, Singh S, Hirten R, Shmidt E, Kesar V, Lasch K, Luo M, Bohm M, Varma S, Fischer M, Hudesman D, Chang S, Lukin D, Sultan K, Swaminath A, Gupta N, Siegel CA, Shen B, Sandborn WJ, Kane S, Loftus EV Jr, Sands BE, Colombel JF, Dulai PS, Ungaro R. Shorter Disease Duration is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease but Not Ulcerative Colitis. *Clin Gastroenterol Hepatol*. 2019 Jan 5.
23. Choy MC, Seah D, **Faleck DM**, Shah SC, Chao CY, An YK, Radford-Smith G, Bessissow T, Dubinsky MC, Ford AC, Churilov L, Yeomans ND, De Cruz PP. Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis. *Inflamm Bowel Dis*. 2019 Jan 3.
24. Soularue E, Lepage P, Colombel JF, Coutzac C, **Faleck D**, Marthey L, Collins M, Chaput N, Robert C, Carbonnel F. Enterocolitis due to immune checkpoint inhibitors: a systematic review. *Gut*. 2018 Nov;67(11):2056-2067.
25. Shmidt E, Kochhar G, Hartke J, Chilukuri P, Meserve J, Chaudrey K, Koliyani-Pace JL, Hirten R, **Faleck D**, Barocas M, Luo M, Lasch K, Boland BS, Singh S, Vande Castele N, Sagi SV, Fischer M, Chang S, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Kane S, Loftus EV Jr, Sandborn WJ, Siegel CA, Sands BE, Colombel JF, Shen B, Dulai PS. Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease. *Inflamm Bowel Dis*. 2018 Oct 12;24(11):2461-2467.
26. Meserve J, Aniwan S, Koliyani-Pace JL, Shashi P, Weiss A, **Faleck D**, Winters A, Chablaney S,

Kochhar G, Boland BS, Singh S, Hirten R, Shmidt E, Hartke JG, Chilukuri P, Bohm M, Sagi SV, Fischer M, Lukin D, Hudesman D, Chang S, Gao Y, Sultan K, Swaminath A, Gupta N, Kane S, Loftus EV Jr, Shen B, Sands BE, Colombel JF, Siegel CA, Sandborn WJ, Dulai PS. Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases. *Clin Gastroenterol Hepatol*. 2018 Sep 27.

27. Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliiani-Pace J, Winters A, Katta L, Shmidt E, Hirten R, **Faleck D**, Parikh MP, Whitehead D, Boland BS, Singh S, Sagi SV, Fischer M, Chang S, Barocas M, Luo M, Lasch K, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Shen B, Kane S, Loftus EV, Siegel CA, Sands BE, Colombel JF, Sandborn WJ, Dulai PS. Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. *Am J Gastroenterol*. 2018 Sep;113(9):1345-1354.
28. **Faleck DM**, Salmasian H, Furuya EY, Larson EL, Abrams JA, Freedberg DE. Proton Pump Inhibitors Do Not Increase Risk for Clostridium difficile Infection in the Intensive Care Unit. *Am J Gastroenterol*. 2016 Nov;111(11):1641-1648.
29. Siegel AB, Goyal A, Salomao M, Wang S, Lee V, Hsu C, Rodriguez R, Hershman DL, Brown RS Jr, Neugut AI, Emond J, Kato T, Samstein B, **Faleck D**, Karagozian R. Serum adiponectin is associated with worsened overall survival in a prospective cohort of hepatocellular carcinoma patients. *Oncology*. 2015;88(1):57-68.
30. Sobey S, Hakimi AA, **Faleck D**, Ghavamian R. Minimally invasive heminephrectomy: feasibility and outcomes. *J Endourol*. 2012 Jul;26(7):866-70.
31. Hakimi AA, **Faleck DM**, Sobey S, Ioffe E, Rabbani F, Donat SM, Ghavamian R. Assessment of complication and functional outcome reporting in the minimally invasive prostatectomy literature from 2006 to the present. *BJU Int*. 2012 Jan;109(1):26-30.
32. Hakimi AA, **Faleck DM**, Agalliu I, Rozenblit AM, Chernyak V, Ghavamian R. Preoperative and intraoperative measurements of urethral length as predictors of continence after robot-assisted radical prostatectomy. *J Endourol*. 2011 Jun;25(6):1025-30.
33. Mason BM, Hakimi AA, **Faleck D**, Chernyak V, Rozenblitt A, Ghavamian R. The role of preoperative endo-rectal coil magnetic resonance imaging in predicting surgical difficulty for robotic prostatectomy. *Urology*. 2010 Nov;76(5):1130-5.
34. **Faleck DM**, Ali K, Roat R, Graham MJ, Crooke RM, Battisti R, Garcia E, Ahima RS, Imai Y. Adipose differentiation-related protein regulates lipids and insulin in pancreatic islets. *Am J Physiol Endocrinol Metab*. 2010 Aug;299(2):E249-57.

#### **BOOK CHAPTERS / E-CHAPTERS**

1. **Faleck D** & Kelsen D. (2023). Colitis-Associated Cancers. *Pediatric Inflammatory Bowel Disease*, 773-788.
2. **Faleck DM**, Greenwald D. (2016). Cholecystitis Empiric Therapy. *Medscape*.

#### **ORAL ABSTRACT PRESENTATIONS**

1. Magahis P, Maron S, King S, Schattner M, Janjigian Y, **Faleck D\***, Laszkowska M\*. Impact of



Helicobacter pylori infection status on outcomes among gastric cancer patients treated with immune checkpoint inhibitors, presented at Digestive Disease Week, May 6-9, 2023.

1. Badran Y, Zou F, Durbin SM, Dutra BE, Abu-Sbeih H, Thomas AS, Altan M, Thompson JA, Qiao W, Leet DE, Lai PY, Horick NK, Postow M, **Faleck DM\***, Wang Y\*, Dougan M\*. Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis, presented at Digestive Disease Week, May 2022 in San Diego, CA.
2. Zou F\*, **Faleck D\***, Thomas A, Harris J, Satish D, Wang X, Charabaty A, Ernstoff MS, Glitza Oliva IC, Hanauer S, McQuade J, Obeid M, Shah A, Richards DM, Sharon E, Wolchok J, Thompson J, Wang Y. Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study, presented at Digestive Disease Week, May 2021 virtual meeting.
3. **Faleck D**, Shashi P, Meserve K, Rahal M, Kadire S, Tran G, Weiss A, Winters A, Chablaney S, Aniwan S, Koliiani-Pace JL, Kochhar G, Boland B, Singh S, Hirten R, Shmidt E, Lasch K, Luo M, Bohm M, Sagi SV, Fischer M, Hudesman D, Chang S, Lukin D, Sultan K, Swaminath A, Gupta N, Siegel CA, Shen B, Sandborn WJ, Sands BE, Colombel JF, Kane S, Loftus EV, Dulai PS. Comparative effectiveness of vedolizumab and TNF-antagonist therapy in ulcerative colitis: a multicenter consortium propensity score-matched analysis, presented at Digestive Disease Week, June 2-5, 2018 in Washington, DC.
4. **Faleck D**, Winters A, Chablaney S, Shashi P, Meserve J, Weiss A, Aniwan S, Koliiani-Pace JL, Kochhar G, Boland B, Singh S, Hirten R, Shmidt E, Lasch K, Luo M, Bohm M, Sagi SV, Fischer M, Hudesman D, Chang S, Lukin D, Sultan K, Swaminath A, Gupta N, Siegel CA, Shen B, Sandborn WJ, Kane S, Loftus EV, Sands BE, Colombel JF, Dulai PS, Ungaro R. Shorter disease duration is associated with higher response rates to vedolizumab in Crohn's disease but not ulcerative colitis: a multi-centre consortium analysis, presented at European Crohn's and Colitis Organization Annual Congress, February 14-17, 2018 in Vienna, Austria.
5. Bohm M, Sagi SV, Fischer M, Kadire S, Tran G, Rahal M, Aniwan S, Meserve J, Weiss A, Kochhar G, Shashi P, **Faleck D**, Winters A, Chablaney S, Koliiani-Pace JL, Boland B, Singh S, Hirten R, Shmidt E, Lasch K, Luo M, Hudesman D, Chang S, Lukin D, Sultan K, Swaminath A, Gupta N, Siegel CA, Kane S, Loftus EV, Sands BE, Sandborn WJ, Colombel JF, Shen B, Dulai PS. Comparative effectiveness of vedolizumab and tumour necrosis factor-antagonist therapy in Crohn's disease: a multicentre consortium propensity score-matched analysis, presented at European Crohn's and Colitis Organization Annual Congress, February 14-17, 2018 in Vienna, Austria.
6. Meserve J, Aniwan S, Koliiani-Pace JL, Shashi P, Weiss A, **Faleck D**, Winters A, Chablaney S, Kochhar G, Boland B, Singh S, Hirten R, Shmidt E, Bohm M, Sagi SV, Fischer M, Lukin D, Hudesman D, Chang S, Sultan K, Swaminath A, Gupta N, Kane S, Loftus EV, Shen B, Sands BE, Colombel JF, Siegel CA, Sandborn WJ, Dulai PS. A multicentre cohort study to assess the safety of vedolizumab for inflammatory bowel disease, presented at European Crohn's and Colitis Organization Annual Congress, February 14-17, 2018 in Vienna, Austria.
7. Lukin D, Weiss A, Aniwan S, Kadire S, Tran G, Rahal M, **Faleck D**, Winters A, Chablaney S, Meserve J, Kochhar G, Shashi P, Koliiani-Pace JL, Bohm M, Sagi SV, Fischer M, Boland B, Singh S, Hirten R, Shmidt E, Hudesman D, Chang S, Sultan K, Swaminath A, Gupta N, Kane S, Loftus

EV, Shen B, Sands BE, Sandborn WJ, Colombel JF, Siegel CA, Dulai PS. Comparative safety profile of vedolizumab and tumour necrosis factor–antagonist therapy for inflammatory bowel disease: a multicentre consortium propensity score-matched analysis, presented at European Crohn’s and Colitis Organization Annual Congress, February 14-17, 2018 in Vienna, Austria.

8. Hudesman D, Chang S, Shashi P, Winters A, Chablaney S, Meserve J, Weiss A, Aniwan S, **Faleck D**, Koliiani-Pace JL, Kochhar G, Boland B, Singh S, Hirten R, Shmidt E, Lasch K, Luo M, Bohm M, Sagi SV, Fischer M, Lukin D, Sultan K, Swaminath A, Gupta N, Siegel CA, Shen B, Kane S, Loftus EV, Sands BE, Sandborn WJ, Colombel JF, Dulai PS. Impact of concomitant immunomodulator use on vedolizumab effectiveness: a multicentre consortium propensity score-matched analysis, presented at European Crohn’s and Colitis Organization Annual Congress, February 14-17, 2018 in Vienna, Austria.

#### **POSTER PRESENTATIONS (SELECT)**

2. Magahis P, Satish D, Laszkowska M, **Faleck D**. Impact of Gastrointestinal Pathogens on Management of Cancer Patients with Diarrhea on Immune Checkpoint Inhibitors. To be presented at Digestive Disease Week, May 6-9, 2023.
3. Satish D, Lin IH, Flory J, Gerdes, H, **Faleck DM**. Exocrine and Endocrine Pancreatic Insufficiency Induced by Immune Checkpoint Inhibitors: A Case-Control Study. Presented at American College of Gastroenterology Annual Meeting, October 21-26, 2022.
4. **Faleck DM**, Sharma K, Yaeger R, Kelsen D. Immune checkpoint inhibitors for colorectal cancer in patients with inflammatory bowel disease. Presented at American College of Gastroenterology Annual Meeting, October 21-26, 2022.
5. Satish D, Laszkowska M, **Faleck DM**. Prevalence and Impact of GI Pathogens in Patients with Diarrhea while on Immune Checkpoint Inhibitors. Presented at Digestive Disease Week, May 21-23, 2021.
6. Abu-Sbeih H, Tang T, **Faleck DM**, Dougan ML, Olsson-Brown A, Johnson DB, Owen DH, Warner DE, Philipp AB, Powell N, Daniels E, Philpott J, Wepler AM, Pinato DJ, and Wang Y. Outcomes of immune checkpoint inhibitor-mediated colitis: Multicenter cohort study. Presented at American Society of Clinical Oncology, Jun 4-8, 2021.
7. Harris JP & **Faleck D**. Efficacy of Infliximab Dose Escalation in Patients With Refractory Immunotherapy-Related Colitis: A Case Series. Presented at Crohn’s & Colitis Virtual Congress, Jan 21-24, 2021.
8. Satish D, Gerdes H, **Faleck D**. Exocrine Pancreatic Insufficiency Induced by Immune Checkpoint Inhibitors: A Case Series. Presented at American College of Gastroenterology Virtual Annual Meeting, October 23-28, 2020.
9. Walid Khaled Chatila, Henry S. Walch, Jamal Benhamida, Jaclyn Frances Hechtman, Francisco M. Barriga, Ritika Kundra, Dorina Ismalgeci, Vincent A. Miller, Karuna Ganesh, **David Faleck**, Nikolaus Schultz, Laura H. Tang, David Paul Kelsen, Rona Yaeger. Genomic alterations in colitis-associated cancers in comparison to those found in sporadic colorectal cancer and present in precancerous dysplasia. Presented at ASCO, 2020.

10. Harris J & **Faleck DM**. Effectiveness of vedolizumab in patients with refractory immunotherapy-related colitis: A case series. Presented at Crohn's & Colitis Congress, Jan 23-35, 2020 in Austin, TX.
11. **Faleck DM**, Shmidt E, Huang R, Katta L, Narula N, Pinotti R, Suarez-Farinas M, Colombel JF. Concomitant steroid therapy with anti-TNF therapy is not more effective than anti-TNF monotherapy in inducing remission in Crohn's disease: A systematic review and pooled meta-analysis of placebo-controlled trials. Presented at Digestive Disease Week 2019, May 18-21, 2019 in San Diego, CA.
12. Feathers A, Lovasi G, Beem K, Grigoryan Z, Datta SK, **Faleck D**, Swaminath A. Crohn's Disease Mortality and Ambient Air Pollution in NYC. Presented at American College of Gastroenterology Annual Meeting, October 25-30, 2019 in San Antonio, TX.
13. Tse SS, Sands BE, Keefer L, Cohen BL, Maser E, Ungaro R, Marion J, Colombel JF, Itzkowitz S, Snyder C, **Faleck D**, Dubinsky MC. High Smoking Cessation Rates in a Pharmacist-Led Clinic Embedded in an IBD Center. Presented at Digestive Disease Week 2019, May 18-21, 2019 in San Diego, CA.
14. Choy MC, Seah D, **Faleck DM**, Shah SC, Al-Khoury A, An YK, Radford-Smith G, Bessissow T, Ford AC, Dubinsky M, Yeomans N, De Cruz P. Infliximab salvage therapy in acute severe ulcerative colitis: A systematic review and meta-analysis, presented at European Crohn's and Colitis Organization Annual Congress, February 14-17, 2018 in Vienna, Austria.
15. Leung G, **Faleck DM**, Colombel JF, Dubinsky M, Berkowitz J, Sultan K, Axelrad J, Cohen ME, Lawlor G, Agrawal M, Lukin DJ, Katz S, Chen LA. Infliximab Re-introduction after Temporary Discontinuation: a Multicentric Survey, presented at Digestive Disease Week 2017, May 6-9, 2017 in Chicago, IL.
16. **Faleck DM**, Salmasian H, Furuya YE, Abrams JA, Freedberg DE. Risk Factors for ICU-Onset *C. difficile* Infection, presented at American College of Gastroenterology Annual Meeting 2014, October 17-22, 2014 in Philadelphia, PA.
17. **Faleck DM**, Swaminath A. Mortality and Cause of Death in Crohn's Disease in NYC, 1993-2010, presented at Digestive Disease Week 2014, May 3-6, 2014 in Chicago, IL.
18. **Faleck DM**, Nafisi A, Gonzalez C. Acute Presentation of Sarcoidosis, presented at the Annual Meeting of the Society of General Internal Medicine, May 4-7, 2011 in Phoenix, AZ.
19. **Faleck DM**, Shapiro EY, Cho JS, Kaye JD, Srinivasan AK, Moldwin RM. Pelvic Floor Dysfunction in the Interstitial Cystitis Population, presented at the Society for Infection and Inflammation in Urology Meeting at the Annual Meeting of the American Urological Association, May 30, 2010, San Francisco, CA.
20. **Faleck DM**, Singhal NS, Scanlan T, Ahima RS. Role of Thyronamines in Energy Homeostasis, presented at the Society for Neuroscience Conference, November 3-7, 2007, San Diego, CA.

## **PEER REVIEW ACTIVITIES**

Peer Reviewer for: American Journal of Gastroenterology, Clinical Gastroenterology & Hepatology, Gastroenterology, Journal for ImmunoTherapy of Cancer, Journal of Immunotherapy and Precision Oncology, The Medical Letter, The Oncologist

**CONSULTING / PHARMACEUTICAL ACTIVITIES**

2023 – Present	Consultant, Janssen Research & Development
2023 – Present	Consultant, Gilead Sciences
2023 – Present	Steering Committee Member, AstraZeneca
2022 – Present	Data Monitoring Committee Member and Consultant, OnQuality Pharmaceuticals
2021 – Present	Trial Steering Committee Member and Consultant, First Wave Biopharma
2021	Special Advisory Board, Kaleido Biosciences
2021	Advisory Board Member, Mallinckrodt Pharmaceuticals
2021	Consultant, Equillium

**ACADEMIC COMMITTEES**

2018 – 2019	Organizing Committee Member, 2nd International Meeting on Treatment Related Toxicities of Hematopoietic Cell Transplantation
2016 – 2018	Project Leader, Gastroenterology Fellowship Quality Improvement Committee, Mount Sinai Hospital
2016 – 2017	Vice Chair of Education, Crohn’s and Colitis Foundation Fellow’s Committee

**PROFESSIONAL MEMBERSHIPS**

2016 – Present	New York Crohn's and Colitis Organization
2015 – Present	Crohn’s and Colitis Foundation
2015 – Present	American Gastroenterological Association
2015 – Present	American College of Gastroenterology
2015 – Present	American Society for Gastrointestinal Endoscopy
2015 – Present	New York Society for Gastrointestinal Endoscopy
2008 – Present	American Medical Association